Home Browse NMDA receptor modulation and severe acute respiratory syndrome treatment
ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
▬
✚
Opinion Article

NMDA receptor modulation and severe acute respiratory syndrome treatment

[version 1; peer review: 2 approved]
Blaise M. Costa
https://orcid.org/0000-0001-6151-2251
Blaise M. Costa
https://orcid.org/0000-0001-6151-2251
PUBLISHED 18 Oct 2021
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the Cheminformatics gateway.

Abstract

N-Methyl-D-aspartate (NMDA) subtype of glutamate receptors is expressed in the human lungs and central nervous system.  NMDA receptor potentiation could increase calcium ion influx and promote downstream signaling mechanisms associated with cellular contractions that are disrupted in severe acute respiratory syndrome. Pharmacological effects generated by triggering glutamate receptor function in the brain, coupled with concurrent stimulation of the respiratory tract, may produce a synergetic effect, improving the airway smooth muscle function. A novel multipronged intervention to simultaneously potentiate NMDA receptors expressed both in the central nervous system and airway muscles would be helpful for the treatment of severe acute respiratory syndrome that deteriorates peripheral and central nervous system function before causing death in humans.

Keywords

NMDA, severe respiratory syndrome (SARS), GluN2D, Potentiator

Corresponding author: Blaise M. Costa
Competing interests: No competing interests were disclosed.
Grant information: The NMDA receptor potentiation research work was funded by American Heart Association Scientist Development Grant to BMC.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Copyright:  © 2021 Costa BM. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite: Costa BM. NMDA receptor modulation and severe acute respiratory syndrome treatment [version 1; peer review: 2 approved]. F1000Research 2021, 10(Chem Inf Sci):1060 (https://doi.org/10.12688/f1000research.73897.1) First published: 18 Oct 2021, 10(Chem Inf Sci):1060 (https://doi.org/10.12688/f1000research.73897.1) Latest published: 18 Oct 2021, 10(Chem Inf Sci):1060 (https://doi.org/10.12688/f1000research.73897.1)

Expression of NMDA receptors in the human lungs

The Human Proteome Project identified abundant expression of NMDA receptor subunits in various organs outside the CNS, including lungs, esophagus, and T-helper cells.1 This finding corroborates a large number of previous reports on the extraneuronal expression of NMDA receptors in various animals.1,4–12 NMDA, when applied to perfused tracheal segments of guinea pigs, increased resting muscle tone and enhanced the contractile response to acetylcholine.13,14 In whole guinea pig lungs, when administered through the trachea, NMDA increased airway perfusion pressure and this increase was abolished by NMDA receptor channel blocker MK-801(4). Following systemic MK-801 administration, adult cats developed apneusis.15,16 In addition, recent studies reveal the critical role of endogenous glutamate in NMDA receptor function during acute lung injury and airway inflammation.4,14,17,18 An NMDA receptor blocker could impair fetal rat lung development.19,20 NMDA receptor activation mediates lung fibroblast proliferation and differentiation in hyperoxia-induced chronic lung disease in newborn rats.20 Acute lung injury, acute respiratory distress syndrome and severe acute respiratory syndrome (SARS) all imply the occurrence of lung injury resulting from direct or indirect respiratory insult.21

The expression of GluN1/2A and 1/2B subtypes were not confirmed in the lung cells, whereas the GluN1/2C subtype was found to be expressed in peripheral and middle-lobe lung samples.4 The GluN1/2D subunit was predominantly expressed in the peripheral, gas-exchange zone of the lungs and in alveolar macrophages; this expression was upregulated in lungs treated with NMDA.4 GluN1 and all four GluN2 subunits were also expressed in the human pulmonary artery smooth muscle cells.22 Overall, these findings indicate that NMDA receptors could control the respiratory tract function in vertebrate animals.23

Kinetics of NMDA receptor subtypes

Glutamate, with concurrent binding of the co-agonist D-serine or glycine, activates NMDA receptors that non-selectively conduct ions across the cells at depolarizing membrane potential which unbinds the otherwise blocking Mg2+ ions. NMDA receptor mediated transport of calcium and sodium ions into the cytoplasm is essential for excitatory cellular events that result in human airway smooth muscle contraction.24 Each non-GluN1 subunit confers distinct spatiotemporal expression and biophysical properties that result in varying agonist affinity, magnesium sensitivity, ion conductance, activation kinetics, open probability, mean open time, cellular localization, and downstream signaling mechanisms.2 In general, diheteromeric NMDA receptors (GluN1/2) exhibit deactivation time constants that span about a 50-fold range, with the following order (from fastest to slowest): NR2A < 2C < 2B << 2D.25 The GluN1/2A subunit-containing NMDA receptor deactivation time constant is about ~50 ms, GluN1/2B ~400 ms, GluN1/2C ~290 ms and GluN1/2D is >1second.25 Since GluN1/2C&D subunits of NMDA receptors are predominantly expressed in the lung epithelial cells and macrophages, and are the slowest channel (among other glutamate receptors) to deactivate, these receptors can conduct a large amount of calcium and sodium ions into the cells and trigger cellular contractions.25–27

Antiviral properties of drugs acting on NMDA receptors

One of the clinically used antiviral agents, amantadine, is a potent NMDA receptor antagonist.28 This drug is also an FDA-approved drug of choice (brand name, Gocovri®) for the treatment of dyskinesia in patients with Parkinson’s disease. An analog of amantadine, memantine (brand name, Namenda®), is one of two FDA-approved clinically used drugs for the treatment of moderate to severe symptoms of Alzheimer’s disease. Since both amantadine and memantine are chemically similar adamantane derivatives, memantine also exerts antiviral effects as previously reported.29 Presumably, these effects could be a collective outcome of activities on host cell glutamate receptors and viral proteins like M2-viroporin.30

Novel NMDA receptor modulators

In recent years, a variety of NMDA receptor modulators have been identified, and they exhibit a broad spectrum of subunit selectivity and mechanisms of action.31–35 These compounds have been largely studied for their activities in neuronal NMDA receptor populations, with the aim of developing treatments for neurological and psychiatric disorders; however, these compounds and their analogs might have therapeutic potential for non-CNS disorders, but this has not yet been explored.

Through our ongoing NMDA receptor drug discovery project, we have identified a compound from PubChem (CID# 3794169), coded as CNS4, and studied its activity on NMDA receptors.36 CNS4 selectively potentiates GluN1/2D receptor currents up to 8-fold, when activated by 100 μM glycine and 0.3μM glutamate, and produces minimal effects on GluN1/2A or 1/2B receptors.36 CNS4 has a variety of other biological activities as reported by the National Center for Advancing Translational Sciences (NCATS); for example: an inconclusive anti-viral activity against influenza-A virus non-structural protein-1 (PubChem AID# 2326); anti-malarial, as an inhibitor of apical membrane antigen-1 of Plasmodium falciparum (AID# 720542); antiprotozoal, as an inhibitor of fructose 1,6- bisphosphate aldolase from Giardia Lamblia (AID# lamblia (2451); and inhibition of nuclear receptor ROR-gamma in the immune cells (AID# 2551 & 2546). The chemical structure of CNS4 and more details on its activities are available at PubChem.

A multipronged approach to treat SARS

An NMDA receptor modulator with antiviral properties could serve as a novel treatment strategy for SARS. Potentiating NMDA receptor activity in the lung epithelial cells will increase calcium ion influx and promote downstream signaling mechanisms associated with cellular contractions that are possibly impaired during SARS. Pharmacological effects generated by triggering neuronal NMDA receptor function, coupled with concurrent potentiation of NMDA receptors expressed in the respiratory tract, could synergistically improve airway smooth muscle contractions. Further, a variety of neurological symptoms were clinically diagnosed in hospitalized COVID-19 patients.37,38 Neuropathogenesis could occur due to the neurologic injury resulting from systemic dysfunction,39 dysregulated renin-angiotensin aldosterone system,40 proinflammatory reactions,41,42 para-infectious and post-infectious triggers,43 and direct viral invasion of the nervous system.44–46 As a well characterized neuropsychiatric drug target,47 with the potential to improve lung function, NMDA receptors could be an ideal focal point for future pharmacological interventions of COVID-19. Clinical conditions involving hypoxia increase blood glutamate concentration by promoting transaminase activity that generates α-keto acids.48–50 Further, neuronal glutamate excitotoxicity induces paralysis in mice after infection by a human coronavirus.51 The connection between disruption in glutamate homeostasis and pathogenesis of various neurological and psychiatric disorders has been extensively studied in the past three decades. Therefore, optimizing glutamatergic signal transmission through neuronal and non-neuronal cell types, that express the major glutamate receptor subtypes like NMDA receptor, could be an appropriate strategy to reduce the extent of lung damage caused by SARS. In this perspective, compounds that modulate NMDA receptors based on glutamate concentration would be an ideal starting point for the development of a treatment approach involving modulation of glutamate signaling at both nerve cells and non-neuronal cells. CNS4 and other recently identified novel glutamate concentration biased NMDA receptor modulators34,35 could serve as lead candidates in the development of clinically useful compounds to treat COVID-19 or other SARS caused by various pathological conditions. Future studies should be carried out in this direction to test this hypothesis.

Conclusion

An increasing body of evidence suggests the expression of functional NMDA receptors in the lungs and their critical role in glutamate induced acute lung injury and acute respiratory distress syndrome.4,13,14,17–20 Despite its direct role in lung injury, little effort has been taken to develop NMDA receptor based therapeutic strategies for the treatment of lung diseases. With the revolution in glutamate receptor pharmacology in the past decade that yielded a variety of chemical tools to modulate NMDA receptors,31–36 and a COVID-19 pandemic that kills humans by primarily affecting lung function, this could be a suitable time to start working on a novel drug target for SARS treatment.

Data availability

No data is associated with this article.

Acknowledgements

Dr. Katherine Jamison is acknowledged for reading this article.

References

  • 1.  Kim MS, Pinto SM, Getnet D, et al.: A draft map of the human proteome. Nature. 2014; 509(7502): 575–81. PubMed Abstract | Publisher Full Text | Free Full Text
  • 2.  Traynelis SF, Wollmuth LP, McBain CJ, et al.: Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev. 2010; 62(3): 405–96. PubMed Abstract | Publisher Full Text | Free Full Text
  • 3.  Paoletti P, Bellone C, Zhou Q: NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 2013; 14(6): 383–400. PubMed Abstract | Publisher Full Text
  • 4.  Dickman KG, Youssef JG, Mathew SM, et al.: Ionotropic glutamate receptors in lungs and airways: molecular basis for glutamate toxicity. Am. J. Respir. Cell Mol. Biol. 2004; 30(2): 139–44. PubMed Abstract | Publisher Full Text
  • 5.  Swanger SA, Traynelis SF: Synaptic Receptor Diversity Revealed Across Space and Time. Trends Neurosci. 2018; 41(8): 486–8. PubMed Abstract | Publisher Full Text
  • 6.  Deng A, Valdivielso JM, Munger KA, et al.: Vasodilatory N-methyl-D-aspartate receptors are constitutively expressed in rat kidney. J. Am. Soc. Nephrol. 2002; 13(5): 1381–4. PubMed Abstract | Publisher Full Text
  • 7.  Erdo SL: Excitatory amino acid receptors in the mammalian periphery. Trends Pharmacol. Sci. 1991; 12(11): 426–9. PubMed Abstract | Publisher Full Text
  • 8.  Genever PG, Wilkinson DJ, Patton AJ, et al.: Expression of a functional N-methyl-D-aspartate-type glutamate receptor by bone marrow megakaryocytes. Blood. 1999; 93(9): 2876–83. PubMed Abstract | Publisher Full Text
  • 9.  Gonzalez-Cadavid NF, Ryndin I, Vernet D, et al.: Presence of NMDA receptor subunits in the male lower urogenital tract. J. Androl. 2000; 21(4): 566–78. PubMed Abstract
  • 10.  Inagaki N, Kuromi H, Gonoi T, et al.: Expression and role of ionotropic glutamate receptors in pancreatic islet cells. FASEB J. 1995; 9(8): 686–91. PubMed Abstract | Publisher Full Text
  • 11.  Krizbai IA, Deli MA, Pestenacz A, et al.: Expression of glutamate receptors on cultured cerebral endothelial cells. J. Neurosci. Res. 1998; 54(6): 814–9. PubMed Abstract | Publisher Full Text
  • 12.  Leung JC, Travis BR, Verlander JW, et al.: Expression and developmental regulation of the NMDA receptor subunits in the kidney and cardiovascular system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002; 283(4): R964–71. PubMed Abstract | Publisher Full Text
  • 13.  Said SI: Glutamate receptors and asthmatic airway disease. Trends Pharmacol. Sci. 1999; 20(4): 132–4. PubMed Abstract | Publisher Full Text
  • 14.  Said SI, Dey RD, Dickman K: Glutamate signalling in the lung. Trends Pharmacol. Sci. 2001; 22(7): 344–5. PubMed Abstract | Publisher Full Text
  • 15.  Feldman JL, Windhorst U, Anders K, et al.: Synaptic interaction between medullary respiratory neurones during apneusis induced by NMDA-receptor blockade in cat. J. Physiol. 1992; 450: 303–23. PubMed Abstract | Publisher Full Text | Free Full Text
  • 16.  Foutz AS, Champagnat J, Denavit-Saubie M: Respiratory effects of the N-methyl-D-aspartate (NMDA) antagonist, MK-801, in intact and vagotomized chronic cats. Eur. J. Pharmacol. 1988; 154(2): 179–84. PubMed Abstract | Publisher Full Text
  • 17.  Said SI, Dickman KG: Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide. Regul. Pept. 2000; 93(1-3): 21–9. PubMed Abstract | Publisher Full Text
  • 18.  Said SI, Pakbaz H, Berisha HI, et al.: NMDA receptor activation: critical role in oxidant tissue injury. Free Radic. Biol. Med. 2000; 28(8): 1300–2. PubMed Abstract | Publisher Full Text
  • 19.  Liao Z, Zhou X, Luo Z, et al.: N-Methyl-D-aspartate Receptor Excessive Activation Inhibited Fetal Rat Lung Development in vivo and In Vitro. Biomed. Res. Int. 2016; 2016: 5843981. PubMed Abstract | Publisher Full Text | Free Full Text
  • 20.  Wang Y, Yue S, Luo Z, et al.: N-methyl-D-aspartate receptor activation mediates lung fibroblast proliferation and differentiation in hyperoxia-induced chronic lung disease in newborn rats. Respir. Res. 2016; 17(1): 136. PubMed Abstract | Publisher Full Text | Free Full Text
  • 21.  Jih TK: Acute respiratory distress syndrome (ARDS) and severe acute respiratory syndrome (SARS): are we speaking different languages?. J. Chin. Med. Assoc. 2005; 68(1): 1–3. PubMed Abstract | Publisher Full Text | Free Full Text
  • 22.  Dong YN, Hsu FC, Koziol-White CJ, et al.: Functional NMDA receptors are expressed by human pulmonary artery smooth muscle cells. Sci. Rep. 2021; 11(1): 8205. PubMed Abstract | Publisher Full Text | Free Full Text
  • 23.  Foutz AS, Champagnat J, Denavit-Saubie M: N-methyl-D-aspartate (NMDA) receptors control respiratory off-switch in cat. Neurosci. Lett. 1988; 87(3): 221–6. PubMed Abstract | Publisher Full Text
  • 24.  Anaparti V, Ilarraza R, Orihara K, et al.: NMDA receptors mediate contractile responses in human airway smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015; 308(12): L1253–64. PubMed Abstract | Publisher Full Text
  • 25.  Cull-Candy SG, Leszkiewicz DN: Role of distinct NMDA receptor subtypes at central synapses. Sci. STKE. 2004; 2004(255): re16. PubMed Abstract | Publisher Full Text
  • 26.  Chen N, Luo T, Raymond LA: Subtype-dependence of NMDA receptor channel open probability. J. Neurosci. 1999; 19(16): 6844–54. PubMed Abstract | Publisher Full Text | Free Full Text
  • 27.  Erreger K, Dravid SM, Banke TG, et al.: Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signalling profiles. J. Physiol. 2005; 563(2): 345–58. PubMed Abstract | Publisher Full Text | Free Full Text
  • 28.  Blanpied TA, Clarke RJ, Johnson JW: Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J. Neurosci. 2005; 25(13): 3312–22. PubMed Abstract | Publisher Full Text | Free Full Text
  • 29.  Brison E, Jacomy H, Desforges M, et al.: Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus. J. Virol. 2014; 88(3): 1548–63. PubMed Abstract | Publisher Full Text | Free Full Text
  • 30.  Wanka L, Iqbal K, Schreiner PR: The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem. Rev. 2013; 113(5): 3516–604. PubMed Abstract | Publisher Full Text | Free Full Text
  • 31.  Monaghan DT, Irvine MW, Costa BM, et al.: Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. Neurochem. Int. 2012; 61(4): 581–92. PubMed Abstract | Publisher Full Text | Free Full Text
  • 32.  Costa BM, Irvine MW, Fang G, et al.: A novel family of negative and positive allosteric modulators of NMDA receptors. J. Pharmacol. Exp. Ther. 2010; 335(3): 614–21. PubMed Abstract | Publisher Full Text | Free Full Text
  • 33.  Mullasseril P, Hansen KB, Vance KM, et al.: A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. Nat. Commun. 2010; 1: 90. PubMed Abstract | Publisher Full Text | Free Full Text
  • 34.  Perszyk R, Katzman BM, Kusumoto H, et al.: An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups. elife. 2018; 7. PubMed Abstract | Publisher Full Text | Free Full Text
  • 35.  Perszyk RE, Swanger SA, Shelley C, et al.: Biased modulators of NMDA receptors control channel opening and ion selectivity. Nat. Chem. Biol. 2020; 16(2): 188–96. PubMed Abstract | Publisher Full Text | Free Full Text
  • 36.  Costa BM, Kwapisz LC, Mehrkens B, et al.: A glutamate concentration-biased allosteric modulator potentiates NMDA-induced ion influx in neurons. Pharmacol. Res. Perspect. 2021; 9(5): e00859. PubMed Abstract | Publisher Full Text | Free Full Text
  • 37.  Pezzini A, Padovani A: Lifting the mask on neurological manifestations of COVID-19. Nat. Rev. Neurol. 2020; 16(11): 636–44. PubMed Abstract | Publisher Full Text | Free Full Text
  • 38.  Mao L, Jin H, Wang M, et al.: Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6): 683–90. PubMed Abstract | Publisher Full Text | Free Full Text
  • 39.  Kanberg N, Ashton NJ, Andersson LM, et al.: Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology. 2020; 95(12): e1754–e1759. PubMed Abstract | Publisher Full Text
  • 40.  Lei Y, Zhang J, Schiavon CR, et al.: SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circ. Res. 2021; 128(9): 1323–6. PubMed Abstract | Publisher Full Text | Free Full Text
  • 41.  Chen G, Wu D, Guo W, et al.: Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 2020; 130(5): 2620–9. PubMed Abstract | Publisher Full Text | Free Full Text
  • 42.  Huang C, Wang Y, Li X, et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506. PubMed Abstract | Publisher Full Text | Free Full Text
  • 43.  Zhao H, Shen D, Zhou H, et al.: Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?. The Lancet Neurology. 2020; 19(5): 383–4. PubMed Abstract | Publisher Full Text | Free Full Text
  • 44.  Song E, Zhang C, Israelow B, et al.: Neuroinvasion of SARS-CoV-2 in human and mouse brain. bioRxiv: the preprint server for biology. 2020.
  • 45.  Meinhardt J, Radke J, Dittmayer C, et al.: Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 2021; 24(2): 168–75. PubMed Abstract | Publisher Full Text
  • 46.  Matschke J, Lütgehetmann M, Hagel C, et al.: Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. The Lancet Neurology. 2020; 19(11): 919–29. PubMed Abstract | Publisher Full Text | Free Full Text
  • 47.  Zhou Q, Sheng M: NMDA receptors in nervous system diseases. Neuropharmacology. 2013; 74: 69–75. PubMed Abstract | Publisher Full Text
  • 48.  Bai W, Li W, Ning YL, et al.: Blood Glutamate Levels Are Closely Related to Acute Lung Injury and Prognosis after Stroke. Front. Neurol. 2017; 8: 755. PubMed Abstract | Publisher Full Text | Free Full Text
  • 49.  Kumazawa K, Ibara S, Kobayashi K, et al.: Changes of blood glutamate levels in hypoxic ischemic encephalopathy patients undergoing brain hypothermia. Hypothermia for Acute Brain Damage: Pathomechanism and Practical Aspects. 2004; 320–24. Publisher Full Text
  • 50.  Gray LR, Tompkins SC, Taylor EB: Regulation of pyruvate metabolism and human disease. Cell. Mol. Life Sci. 2014; 71(14): 2577–604. PubMed Abstract | Publisher Full Text | Free Full Text
  • 51.  Brison E, Jacomy H, Desforges M, et al.: Glutamate excitotoxicity is involved in the induction of paralysis in mice after infection by a human coronavirus with a single point mutation in its spike protein. J. Virol. 2011; 85(23): 12464–73. PubMed Abstract | Publisher Full Text | Free Full Text

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 18 Oct 2021
Comment
Author details Author details
Competing interests
Grant information
Article Versions (1)
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
 - -
Citations
SEE MORE DETAILS
CITE
how to cite this article
Costa BM. NMDA receptor modulation and severe acute respiratory syndrome treatment [version 1; peer review: 2 approved]. F1000Research 2021, 10(Chem Inf Sci):1060 (https://doi.org/10.12688/f1000research.73897.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 18 Oct 2021
Views
10
Cite
Reviewer Report 12 Dec 2022
Jaewon Ko, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, South Korea 
Approved
VIEWS 10
https://doi.org/10.5256/f1000research.77586.r157840
This short article states that modulation of an NMDA receptor (NMDAR) function with anti-viral properties could be beneficial for treating disorders that involve NMDAR dysfunctions. The author first summarized known facts for distinct NMDAR subunits expressed in lung cells (i.e., ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Ko J. Reviewer Report For: NMDA receptor modulation and severe acute respiratory syndrome treatment [version 1; peer review: 2 approved]. F1000Research 2021, 10(Chem Inf Sci):1060 (https://doi.org/10.5256/f1000research.77586.r157840)
The direct URL for this report is:
https://f1000research.com/articles/10-1060/v1#referee-response-157840
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Report a concern
Views
29
Cite
Reviewer Report 25 Jul 2022
James Pearle, California Research Medical Group, Fullerton, USA 
Approved
VIEWS 29
https://doi.org/10.5256/f1000research.77586.r142691
In severe acute respiratory distress syndrome, cellular contractions may be disrupted. 

By triggering glutamate receptor function in the brain and with stimulation of the respiratory tract, a synergetic effect may improve airways smooth muscle function and neurologic ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Pearle J. Reviewer Report For: NMDA receptor modulation and severe acute respiratory syndrome treatment [version 1; peer review: 2 approved]. F1000Research 2021, 10(Chem Inf Sci):1060 (https://doi.org/10.5256/f1000research.77586.r142691)
The direct URL for this report is:
https://f1000research.com/articles/10-1060/v1#referee-response-142691
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Report a concern

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 18 Oct 2021
Comment

Open Peer Review

Reviewer Status

Alongside their report, reviewers assign a status to the article:

Approved
The paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved
Fundamental flaws in the paper seriously undermine the findings and conclusions

Reviewer Reports

Invited Reviewers
1 2
Version 1
18 Oct 21 		read read
  1. James Pearle, California Research Medical Group, Fullerton, USA
  2. Jaewon Ko, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, South Korea

Comments on this article

All Comments(0)

Add a comment
Sign up for content alerts

Browse by related subjects

    keyboard_arrow_left Back to all reports
    keyboard_arrow_left Back to all reports
    Alongside their report, reviewers assign a status to the article:
    Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
    Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
    Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
    Sign In
    If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

    The email address should be the one you originally registered with F1000.
    Email address not valid, please try again

    You registered with F1000 via Google, so we cannot reset your password.

    To sign in, please click here.

    If you still need help with your Google account password, please click here.

    You registered with F1000 via Facebook, so we cannot reset your password.

    To sign in, please click here.

    If you still need help with your Facebook account password, please click here.

    Code not correct, please try again
    Email us for further assistance.
    Server error, please try again.